This piece covers HEICO, a company that makes cheaper FAA-approved replacement parts for planes (like generic drugs), with 8 billion parts and zero safety incidents. The author sees HEICO as a compounding machine, run by a disciplined family that thinks like owners—sales grew 15% a year for 30 years, shareholder returns 21%. Key holdings: HEICO (long-term buy), TransDigm (a more aggressive rival that cooperates more than competes), and Wencore (acquired, adding 7,000 parts).
This issue features an analysis of HEICO by Ironvine Capital analyst Eric Ruden, a family-run company that occupies a subtle niche in the aerospace parts and maintenance market. Ruden likens HEICO's PMA business to "generic drugs" — after receiving FAA certification, it replicates OEM parts at extremely low R&D costs, sells them at a 30%–40% discount, and builds trust with a spotless quality record (8 billion+ parts, 0 fleet groundings). Core thesis: HEICO is a "compounding machine" — since the Mendelson family took over in 1990, sales have grown at a 15% CAGR, net profit at 18%, and shareholder returns at 21%, with this formula heavily dependent on management's capital allocation discipline of "thinking like owners."
Eric Ruden argues that HEICO's PMA (Parts Manufacturer Approval) business serves as a "second low-cost source" challenging OEM monopoly, with its core being the provision of alternatives that are identical in "form, fit, and function" to OEM parts, yet 30%-40% cheaper.
Falsification signal: If a single part accident caused by HEICO leads to an air disaster, the entire PMA industry would face catastrophic consequences; however, the company's record of 8+ billion parts with zero service bulletins/zero in-flight shutdowns provides historical backing.
Ruden emphasizes that the capital allocation discipline of the Mendelson family (Larry and his two sons Eric and Victor) is the core of HEICO's compounding: 98 acquisitions completed in 34 years, only 2 divestitures, and cumulative restructuring/impairment charges under $10 million.
Projection: Future M&A opportunities may shift from aircraft parts to small niches in electronic technology (ETG). Management has explicitly stated that "even if no new PMA parts are developed, a 15% net profit growth can still be achieved through other areas."
Ruden points out that HEICO's financial model is a classic example of "low capital intensity, high cash flow conversion": FCF conversion exceeds net profit by 130%, mainly because depreciation and amortization far exceed actual capital expenditure.
Extrapolation: HEICO's ETG business still posted positive growth during the 2020 pandemic (due to the counter-cyclical nature of defense budgets), while FSG's organic growth was only -10% in 2008, demonstrating a strong cyclical buffer capability.
Ruden identifies three major risks but argues that HEICO's defensive design has allowed it to "successfully navigate through" multiple historical downturns.
Disproof Signal: If HEICO continues to expand into OEM's core "life-limited parts" territory, it could trigger a full-scale price war; if future M&A margins are significantly lower than historical averages, the compounding formula may break down.
| Position | Guest Attitude | Key Data |
|---|---|---|
| HEICO | Favorable (long-term hold) | Sales CAGR of 15% since 1990; net profit CAGR of 18%; shareholder return of 21% |
| TransDigm | Comparison target ("devil" partner) | 300,000+ parts vs. HEICO's 19,500; high leverage, aggressive pricing |
| Wencore | Acquired and integrated | Second-largest PMA player pre-acquisition, 7,000 parts, only 10%-15% overlap with HEICO |
| Boeing / Airbus | Industry backdrop | Global duopoly, OEM spare parts profit pool far exceeds initial sales |
| Pratt & Whitney | Historical event linkage | 1985 engine fire catalyzed PMA, $1 million lawsuit with HEICO |
| Lufthansa | Strategic partner | Invested 20% equity stake in 1997, still holds; provides technical data and anchor customer |
| Lockheed | Downstream customer | Cost-plus contracts, lower negotiation intensity vs. Boeing |
1. “PMA 是航空业的仿制药”——Eric Ruden
Support: HEICO 以 OEM 30%-40% 的价格提供形式、配合、功能完全一致的零件,但无需研发成本,且通过 FAA 单独认证的难度高于 OEM 初始认证。
2. “HEICO 只取 30% 市场份额,然后停下”
Support: 贡献利润率模型显示,一旦超过 30%,OEM 会被迫降价,进而摧毁 PMA 的定价优势(“囚徒困境”)。
3. “Mendelson 家族是‘天使’,TransDigm 是‘魔鬼’,但两者能共存”
Support: HEICO 低杠杆、客户友好;TransDigm 高杠杆、激进涨价。两者产品组合重叠极少,实际合作多于竞争(如 Wencore 为 TransDigm 分销)。
4. “80 亿零件、0 次空中关停——这是 PMA 最大的护城河”
Support: HEICO 历史上从未因零件问题导致事故,对比 OEM 普遍无法做到,这抵消了“非原厂”的信任赤字。
5. “M&A 的纪律:34 年仅 2 次剥离,累计减值不足 $1000 万”
Support: 98 笔收购平均现金倍数中等个位数,企业家保留 20% 股权,90% 创始人仍在职,形成“永续收购机器”。
6. “HEICO 的 FCF 转化率超 130%——折旧/摊销远超实际维护支出”
Support: 低资本密集型模型(无需研发支出),现金利润率比 GAAP 利润率高 5 个百分点。
7. “COVID 期间有机增长 -44%,但比对手好 10 个百分点”
Support: 竞争对手同期 -50% 至 -60%,因 PMA 在航空成本压力下反而加速被采用,且一旦采用几乎无回头可能。
8. “Mendelson 家族的‘最后机会’:如果不再做 PMA,就去买冰淇淋摊——只要利润率 20%”
Support: 管理层公开表示,即使 PMA 开发停止,他们也能通过其他行业实现 15% 净利增长,反映其资本配置灵活性与机会主义文化。